REMARKS

Reconsideration of this application is requested in view of the amendments to the claims and the remarks presented herein.

The claims in the application are claims 5, 24, 26 and 27, all other claims having been cancelled.

The Examiner, after considering the appeal brief, was of the opinion that the application was patentable for the reasons set forth therein. However, the Examiner upon a further update of the search for allowance, ran across U.S. Patent No. 6,207,832 and this was called to the undersigned's attention.

The present claims are free from the scope of the Curran et al patent newly cited by the Examiner. While the reference is directed to homocamphtothecin derivatives wherein in the 7-position of the reference, Applicants' substituents R₆ is substituted with -Si(R⁸R⁹R¹⁰) which is similar to Applicants' substituent R₆. However, Applicants' claims further define Applicants' substituents R₂, R₃ and R₄ as at least one being -OSO₂R₁₀ and this substituent is completely lacking from the reference cited by the Examiner and therefore, it neither anticipates nor renders obvious Applicants' presently claimed compounds.

Since the claims were initially found to be allowable with the exception of the Curran et al patent, it is believed that the present claims clearly distinguish therefrom and favorable reconsideration of this application is requested.

Respectfully submitted, Muserlian, Lucas and Mercanti

Charles A. Muserlian, 19,683 Attorney for Applicants Tel.# (212) 661-8000

CAM:ds Enclosures

CERTIFICATION OF FACSIMILE TRANSMISSION

i necessitive that this paper is b	eing facsimile transmitted to the Patent and
Trademark Office on the date shown below	w.
Charles A. Muserlian	Date: <u>November 3, 2004</u>